A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ALXN1101 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2019
Price : $35 *
At a glance
- Drugs Fosdenopterin (Primary)
- Indications Molybdenum cofactor deficiency
- Focus Adverse reactions; First in man
- Sponsors Alexion Pharmaceuticals; Origin Biosciences
- 05 Nov 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 05 Nov 2013 New trial record
- 01 Nov 2013 Status changed from recruiting to discontinued, according to ClinicalTrials.gov.